HC Wainwright & Co. initiated coverage on Agenus with a new price target
$AGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
HC Wainwright & Co. initiated coverage of Agenus with a rating of Buy and set a new price target of $12.00